GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intervacc AB (OSTO:IVACC) » Definitions » Total Liabilities

Intervacc AB (OSTO:IVACC) Total Liabilities : kr18.30 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Intervacc AB Total Liabilities?

Intervacc AB's Total Liabilities for the quarter that ended in Mar. 2024 was kr18.30 Mil.

Intervacc AB's quarterly Total Liabilities increased from Sep. 2023 (kr18.17 Mil) to Dec. 2023 (kr21.68 Mil) but then declined from Dec. 2023 (kr21.68 Mil) to Mar. 2024 (kr18.30 Mil).

Intervacc AB's annual Total Liabilities declined from Dec. 2021 (kr21.14 Mil) to Dec. 2022 (kr14.88 Mil) but then increased from Dec. 2022 (kr14.88 Mil) to Dec. 2023 (kr21.68 Mil).


Intervacc AB Total Liabilities Historical Data

The historical data trend for Intervacc AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intervacc AB Total Liabilities Chart

Intervacc AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.25 17.67 21.14 14.88 21.68

Intervacc AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.28 19.35 18.17 21.68 18.30

Intervacc AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Intervacc AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.538+(0.142+-5.2735593669695E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=21.68

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=259.611-237.931
=21.68

Intervacc AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.17+(0+0.133
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=18.30

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=238.844-220.541
=18.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intervacc AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Intervacc AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Intervacc AB (OSTO:IVACC) Business Description

Traded in Other Exchanges
Address
Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.

Intervacc AB (OSTO:IVACC) Headlines

No Headlines